- Home
- PLX vs ARCT Comparison
PLX vs ARCT Comparison
Compare PLX & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLX | ARCT |
|---|---|---|
| Founded | 1993 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.9M | 369.5M |
| IPO Year | 1996 | 2019 |
Fundamental Metrics
Financial Performance| Metric | PLX | ARCT |
|---|---|---|
| Price | $2.64 | $10.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $23.80 |
| AVG Volume (30 Days) | ★ 801.0K | 736.3K |
| Earning Date | 08-12-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.00 |
| EPS | ★ 0.27 | N/A |
| Revenue | $52,744,000.00 | ★ $82,031,000.00 |
| Revenue This Year | $55.77 | N/A |
| Revenue Next Year | N/A | $64.21 |
| P/E Ratio | $10.00 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.65 | $5.50 |
| 52 Week High | $3.19 | $24.14 |
Technical Indicators
Market Signals| Indicator | PLX | ARCT |
|---|---|---|
| Relative Strength Index (RSI) | 46.73 | 36.07 |
| Support Level | $2.59 | $6.53 |
| Resistance Level | $2.75 | $17.85 |
| Average True Range (ATR) | 0.10 | 1.11 |
| MACD | -0.02 | -0.42 |
| Stochastic Oscillator | 20.00 | 4.67 |
Price Performance
Historical ComparisonAbout PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.